Skip to main content

Table 4 Pooled estimates for BCVA change from baseline for PDT versus anti-VEGF

From: Photodynamic therapy versus anti-vascular endothelial growth factor agents for polypoidal choroidal vasculopathy: A meta-analysis

Outcome of Interest Studies (n) WMD/OR (95 % CI) Test for Overall Effect Study Heterogeneity
χ2 p I2
LogMAR Change in both Groups (PDT group vs anti-VEGF group) (3mo)
Design       
 All trials 5 −0.02 (−0.12, 0.08) Z =0.45, P =0.653 6.77 0.148 40.9 %
 Retro 4 −0.05 (−0.18, 0.07) Z =0.85, P =0.407 5.10 0.165 41.2 %
 RCT 1 0.05 (−0.07, 0.17) Z =0.83, P =0.407   -  
Anti-VEGF agents       
 All trials 5 −0.02 (−0.12, 0.08) Z =0.45, P =0.653 6.77 0.148 40.9 %
 Ranibizumab 3 −0.03 (−0.20, 0.13) Z =0.39, P =0.694 6.71 0.035 70.2 %
 Non- Ranibizumab 2 −0.02 (−0.16, 0.12) Z =0.32, P =0.749 0.02 0.859 0.00 %
LogMAR Change in both Groups (PDT group vs anti-VEGF group) (6mo)
Design       
 All trials 4 0.02 (−0.12, 0.16) Z =0.23, P =0.817 7.60 0.055 60.5 %
 Retro 3 −0.03 (−0.22, 0.17) Z =0.25, P =0.800 5.74 0.057 65.2 %
 RCT 1 0.10 (−0.02, 0.22) Z =1.66, P =0.097   -  
Anti-VEGF agents       
 All trials 4 0.02 (−0.12, 0.16) Z =0.23, P =0.817 7.60 0.055 60.5 %
 Ranibizumab 3 0.02 (−0.15, 0.20) Z =0.27, P =0.787 7.21 0.027 72.3 %
 Non- Ranibizumab 1 −0.03 (−0.27, 0.21) Z =0.25, P =0.806   -  
LogMAR Improvements in both Groups (PDT group vs anti-VEGF group) (12mo)
Design       
 All trials 4 0.02 (−0.15, 0.18) Z =0.20, P =0.839 10.43 0.015 71.2 %
 Retro 3 −0.04 (−0.24, 0.16) Z =0.40, P =0.690 5.99 0.050 66.6 %
 RCT 1 0.15 (0.03, 0.27) Z =2.49, P =0.013   -  
Anti-VEGF agents       
 All trials 4 0.02 (−0.15, 0.18) Z =0.20, P =0.839 10.43 0.015 71.2 %
 Ranibizumab 3 0.03 (−0.17, 0.24) Z =0.31, P =0.760 9.63 0.009 79.0 %
 Non- Ranibizumab 1 −0.05 (−0.29, 0.19) Z =0.41, P =0.682   -  
LogMAR Improvements in both Groups (PDT group vs anti-VEGF group) (24mo)
 All trials 2 −0.17 (−0.90, 0.55) Z =0.47, P =0.638 19.1 P < 0.001 94.8 %
LogMAR Change as Categorical Variable
Proportion of eyes with improved vision
 final visit 5 1.24 (0.54, 2.85) Z =0.51, P =0.610 7.47 0.113 46.4 %
Proportion of eyes with deteriorated vision
 final visit 5 1.40 (0.42, 4.73) Z =0.55, P =0.586 11.23 0.024 64.4 %
Proportion of eyes with stable vision
 final visit 5 0.56 (0.29, 1.10) Z =1.67, P =0.094 6.82 0.145 41.4 %
  1. PDT photodynamic therapy; VEGF vascular endothelial growth factor; WMD weighted mean differences; OR odds ratio; CI confidence interval; Retro retrospective comparative study; RCT prospective randomized controlled trial